Compare Stocks: KRYS, BIIB, ALNY, and INSM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$236.22 +3.0%	$267.02	$197.81 ▼ $495.55	$31.61B	0.3	2.35 million shs	1.90 million shs
BIIB Biogen	$216.78 +1.1%	$205.53	$131.52 ▼ $222.15	$32.03B	0.17	957,736 shs	722,347 shs
INSM Insmed	$125.77 +0.6%	$111.05	$90.39 ▼ $212.75	$27.47B	0.81	3.13 million shs	1.12 million shs
KRYS Krystal Biotech	$346.58 +2.8%	$347.03	$136.73 ▼ $382.54	$10.26B	0.53	327,522 shs	407,794 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+3.31%	-12.10%	-20.58%	-48.46%
BIIB Biogen	0.00%	+3.31%	+8.06%	+11.88%	+55.97%
INSM Insmed	0.00%	+1.64%	+17.09%	+18.38%	-2.84%
KRYS Krystal Biotech	0.00%	+4.31%	+5.83%	+15.74%	+137.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$236.22 +3.0%	$267.02	$197.81 ▼ $495.55	$31.61B	0.3	2.35 million shs	1.90 million shs
BIIB Biogen	$216.78 +1.1%	$205.53	$131.52 ▼ $222.15	$32.03B	0.17	957,736 shs	722,347 shs
INSM Insmed	$125.77 +0.6%	$111.05	$90.39 ▼ $212.75	$27.47B	0.81	3.13 million shs	1.12 million shs
KRYS Krystal Biotech	$346.58 +2.8%	$347.03	$136.73 ▼ $382.54	$10.26B	0.53	327,522 shs	407,794 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+3.31%	-12.10%	-20.58%	-48.46%
BIIB Biogen	0.00%	+3.31%	+8.06%	+11.88%	+55.97%
INSM Insmed	0.00%	+1.64%	+17.09%	+18.38%	-2.84%
KRYS Krystal Biotech	0.00%	+4.31%	+5.83%	+15.74%	+137.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.96	Moderate Buy	$386.62	63.67% Upside
BIIB Biogen	2.58	Moderate Buy	$227.07	4.75% Upside
INSM Insmed	3.00	Buy	$205.52	63.41% Upside
KRYS Krystal Biotech	2.92	Moderate Buy	$365.40	5.43% Upside

Current Analyst Ratings Breakdown

Latest KRYS, BIIB, ALNY, and INSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$318.00
8/18/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/18/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00
8/14/2026	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$316.00 ➝ $256.00
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00
8/13/2026	BIIB Biogen	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$300.00
8/12/2026	BIIB Biogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
8/10/2026	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$185.00 ➝ $195.00
8/10/2026	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/10/2026	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$179.00 ➝ $175.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$4.80B	6.58	$2.80 per share	84.48	$10.12 per share	23.34
BIIB Biogen	$10.03B	3.19	$22.63 per share	9.58	$127.56 per share	1.70
INSM Insmed	$606.42M	45.29	N/A	N/A	$3.47 per share	36.24
KRYS Krystal Biotech	$389.13M	26.36	$7.29 per share	47.54	$45.92 per share	7.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	43.91	24.48	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	38.37	13.32	6.75	8.32%	11.18%	6.88%	10/29/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	48.19	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	43.43	37.15	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)

Latest KRYS, BIIB, ALNY, and INSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BIIB Biogen	0.39	1.87	1.26
INSM Insmed	0.74	3.72	3.40
KRYS Krystal Biotech	N/A	8.32	7.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
INSM Insmed	N/A
KRYS Krystal Biotech	86.29%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
INSM Insmed	2.10%
KRYS Krystal Biotech	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable
KRYS Krystal Biotech	210	29.60 million	25.72 million	Optionable

KRYS, BIIB, ALNY, and INSM Headlines

Recent News About These Companies

Deutsche Bank AG Takes Position in Krystal Biotech, Inc. $KRYS

August 23 at 3:43 AM | marketbeat.com

William Blair Investment Management LLC Acquires New Stake in Krystal Biotech, Inc. $KRYS

August 22 at 6:31 AM | marketbeat.com

BlackRock Inc. Makes New $1.55 Billion Investment in Krystal Biotech, Inc. $KRYS

August 21 at 3:21 AM | marketbeat.com

Lisanti Capital Growth LLC Takes Position in Krystal Biotech, Inc. $KRYS

August 20 at 6:16 AM | marketbeat.com

TimesSquare Capital Management LLC Makes New Investment in Krystal Biotech, Inc. $KRYS

August 18, 2026 | marketbeat.com

Krystal Biotech (KRYS) Has a New Rating from RBC Capital

August 17, 2026 | theglobeandmail.com

Krystal Biotech (NASDAQ:KRYS) Earns Moderate Buy Rating from Analysts at Royal Bank Of Canada

August 17, 2026 | americanbankingnews.com

State of Wyoming Buys New Stake in Krystal Biotech, Inc. $KRYS

August 16, 2026 | marketbeat.com

Krystal Biotech (NASDAQ:KRYS) Upgraded to "Moderate Buy" at Royal Bank Of Canada

August 15, 2026 | marketbeat.com

Krystal Biotech (NASDAQ:KRYS) Director Sells 25,000 Shares

August 15, 2026 | insidertrades.com

Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

August 14, 2026 | marketbeat.com

Here are Friday’s top Wall Street analyst research calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, SanDisk, T-Mobile US, Wayfair, and ...

August 14, 2026 | msn.com

Bank of America Corp DE Increases Stock Position in Krystal Biotech, Inc. $KRYS

August 11, 2026 | marketbeat.com

Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript

August 10, 2026 | finance.yahoo.com

Renaissance Technologies LLC Has $2.48 Million Stock Position in Krystal Biotech, Inc. $KRYS

August 10, 2026 | marketbeat.com

Krystal Biotech (NASDAQ:KRYS) Upgraded at Chardan Capital

August 6, 2026 | marketbeat.com

California State Teachers Retirement System Has $6.76 Million Holdings in Krystal Biotech, Inc. $KRYS

August 6, 2026 | marketbeat.com

Citi Reaffirms Their Buy Rating on Krystal Biotech (KRYS)

August 5, 2026 | theglobeandmail.com

Krystal Biotech, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 5, 2026 | seekingalpha.com

Krystal Biotech, Inc. Q2 2026 Earnings Call Summary

August 5, 2026 | finance.yahoo.com

Krystal Biotech Earnings Call Signals Profitable Growth

August 4, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS, BIIB, ALNY, and INSM Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$236.22 +6.92 (+3.02%)

As of 08/21/2026 04:00 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$216.78 +2.43 (+1.13%)

As of 08/21/2026 04:00 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Insmed NASDAQ:INSM

$125.77 +0.69 (+0.55%)

As of 08/21/2026 04:00 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Krystal Biotech NASDAQ:KRYS

$346.58 +9.56 (+2.84%)

As of 08/21/2026 04:00 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRYS, BIIB, ALNY, and INSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRYS, BIIB, ALNY, and INSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRYS, BIIB, ALNY, and INSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS, BIIB, ALNY, and INSM Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Insmed NASDAQ:INSM

Krystal Biotech NASDAQ:KRYS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRYS, BIIB, ALNY, and INSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRYS, BIIB, ALNY, and INSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRYS, BIIB, ALNY, and INSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS, BIIB, ALNY, and INSM Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Insmed NASDAQ:INSM

Krystal Biotech NASDAQ:KRYS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools